Published in Clin Infect Dis on September 01, 2011
Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis (2014) 3.09
A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. Am Psychol (2013) 2.27
Phylogenetic insights into regional HIV transmission. AIDS (2012) 1.18
Treatment outcomes in undocumented Hispanic immigrants with HIV infection. PLoS One (2013) 1.11
Cell phone utilization among foreign-born Latinos: a promising tool for dissemination of health and HIV information. J Immigr Minor Health (2014) 1.00
HIV risk behaviors and sociodemographic features of HIV-infected Latinos residing in a new Latino settlement area in the Southeastern United States. AIDS Care (2013) 0.95
Latinos and HIV care in the Southeastern United States: new challenges complicating longstanding problems. Clin Infect Dis (2011) 0.94
Evolving character of chronic central nervous system HIV infection. Semin Neurol (2014) 0.89
Molecular epidemiology of tuberculosis in foreign-born persons living in San Francisco. Am J Respir Crit Care Med (2013) 0.82
Human Immunodeficiency Virus Infection Newly Diagnosed at Autopsy in New York City, 2008-2012. Open Forum Infect Dis (2015) 0.80
Synthetic chondramide A analogues stabilize filamentous actin and block invasion by Toxoplasma gondii. J Nat Prod (2013) 0.79
Spatial epidemiology of recently acquired HIV infections across rural and urban areas of North Carolina. PLoS One (2014) 0.79
The impact of ethnicity/race on the association between the Veterans Aging Cohort Study (VACS) Index and neurocognitive function among HIV-infected persons. J Neurovirol (2015) 0.78
What's pregnancy got to do with it? Late presentation to HIV/AIDS services in Northeastern Brazil. AIDS Care (2014) 0.78
Factors associated with late presentation for HIV/AIDS care in Harare City, Zimbabwe, 2015. BMC Public Health (2016) 0.78
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo). Antimicrob Agents Chemother (2012) 0.78
HIV Transmission Patterns Among Immigrant Latinos Illuminated by the Integration of Phylogenetic and Migration Data. AIDS Res Hum Retroviruses (2015) 0.77
HIV-Related Stigma Among Spanish-speaking Latinos in an Emerging Immigrant Receiving City. J Immigr Minor Health (2016) 0.77
HIV testing practices among Latina women at risk of getting infected: a five-year follow-up of a community sample in South Florida. AIDS Care (2015) 0.77
¡Sólo Se Vive Una Vez! (You Only Live Once): A Pilot Evaluation of Individually Tailored Video Modules Aiming to Increase HIV Testing Among Foreign-Born Latino Men. J Acquir Immune Defic Syndr (2017) 0.77
Population-Based Estimates of Life Expectancy After HIV Diagnosis: United States 2008-2011. J Acquir Immune Defic Syndr (2016) 0.77
Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010. AIDS Res Treat (2012) 0.76
Factors Associated with Sexual Risk of HIV Transmission Among HIV-Positive Latino Men Who have Sex with Men on the U.S.-México Border. AIDS Behav (2016) 0.75
The prevalence and associated factors for delayed presentation for HIV care among tuberculosis/HIV co-infected patients in Southwest Ethiopia: a retrospective observational cohort. Infect Dis Poverty (2016) 0.75
Toxoplasma Effectors Targeting Host Signaling and Transcription. Clin Microbiol Rev (2017) 0.75
Significant association between perceived HIV related stigma and late presentation for HIV/AIDS care in low and middle-income countries: A systematic review and meta-analysis. PLoS One (2017) 0.75
Delayed entry into HIV care after diagnosis in two specialized care and treatment centres in Cameroon: the influence of CD4 count and WHO staging. BMC Public Health (2016) 0.75
Acceptability of Rapid HIV Testing Among Latinos in Washington Heights, New York City, New York, USA. J Immigr Minor Health (2016) 0.75
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep (1992) 22.29
Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol (2003) 18.01
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA (2001) 7.63
The impact of homophobia, poverty, and racism on the mental health of gay and bisexual Latino men: findings from 3 US cities. Am J Public Health (2001) 6.98
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J Acquir Immune Defic Syndr (2006) 2.89
Late presentation of HIV infection: a consensus definition. HIV Med (2011) 2.67
HIV prevention with Mexican migrants: review, critique, and recommendations. J Acquir Immune Defic Syndr (2004) 2.63
Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis (2002) 2.57
Late HIV testing - 34 states, 1996-2005. MMWR Morb Mortal Wkly Rep (2009) 2.53
Defining urban and rural areas in U.S. epidemiologic studies. J Urban Health (2006) 2.26
Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr (2004) 2.22
Factors associated with delayed initiation of HIV medical care among infected persons attending a southern HIV/AIDS clinic. South Med J (2006) 1.88
Late diagnosis of HIV infection: the role of age and sex. Am J Med (2007) 1.86
Characteristics of HIV infection among Hispanics, United States 2003-2006. J Acquir Immune Defic Syndr (2008) 1.79
Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS (2007) 1.78
Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care (2006) 1.76
Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr (2008) 1.47
Connecting the dots: when the risks of HIV/STD infection appear high but the burden of infection is not known--the case of male Latino migrants in the southern United States. AIDS Behav (2007) 1.46
Reported HIV status of tuberculosis patients--United States, 1993-2005. MMWR Morb Mortal Wkly Rep (2007) 1.45
Factors in the delayed HIV presentation of immigrants in Northern California: implications for voluntary counseling and testing programs. J Immigr Minor Health (2007) 1.41
Delayed presentation for human immunodeficiency virus (HIV) care among veterans: a problem of access or screening? Med Care (2007) 1.32
Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. AIDS (2006) 1.30
Factors associated with late HIV testing for Latinos diagnosed with AIDS in Los Angeles. AIDS Care (2009) 1.29
Predictors of delayed HIV diagnosis in a recently diagnosed cohort. AIDS Patient Care STDS (2007) 1.27
Racial/ethnic differences in CD4 T cell count and viral load at presentation for medical care and in follow-up after HIV-1 infection. AIDS (2002) 1.19
Late HIV diagnosis in Houston/Harris County, Texas, 2000-2007. AIDS Care (2010) 1.09
Increases in HIV diagnoses at the U.S.-Mexico border, 2003-2006. AIDS Educ Prev (2009) 1.02
HIV-tuberculosis coinfection in Southern California: evaluating disparities in disease burden. Am J Public Health (2010) 0.94
Unique aspects of the care of HIV-positive Latino patients living in the United States. Curr HIV/AIDS Rep (2010) 0.91
Estimation of the prevalence of AIDS, opportunistic infections, and standard of care among patients with HIV/AIDS receiving care along the U.S.-Mexico border through the Special Projects of National Significance: a cross-sectional study. AIDS Patient Care STDS (2008) 0.85
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med (2003) 3.32
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA (2002) 2.94
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Frequent detection of acute primary HIV infection in men in Malawi. AIDS (2004) 2.43
Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest (2004) 2.30
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS (2008) 2.25
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS (2011) 2.22
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Moving forward in HIV-associated cancer. J Clin Oncol (2014) 2.14
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. PLoS Med (2011) 2.06
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.02
Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr (2006) 2.01
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 1.99
Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children. Int J Epidemiol (2009) 1.96
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med (2003) 1.96
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis (2011) 1.91
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care (2006) 1.76
Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis (2005) 1.76
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med (2014) 1.75
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS (2004) 1.74
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Splines for trend analysis and continuous confounder control. Epidemiology (2011) 1.69
Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis (2011) 1.68
Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol (2009) 1.63
Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr (2002) 1.59
Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. AIDS Res Hum Retroviruses (2010) 1.58
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. J Immunol (2012) 1.57
Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis (2013) 1.55
Targeted screening for Trichomonas vaginalis with culture using a two-step method in women presenting for STD evaluation. Sex Transm Dis (2004) 1.54
Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr (2005) 1.52
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis (2003) 1.51
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr (2004) 1.48
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Ann Intern Med (2015) 1.47
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis (2010) 1.45
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis (2011) 1.45
Frequent detection of acute HIV infection in pregnant women. AIDS (2007) 1.43
Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int (2005) 1.40
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr (2006) 1.40
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.39
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS (2012) 1.38
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis (2006) 1.37
Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother (2012) 1.36
Virologic and immunologic response to HAART, by age and regimen class. AIDS (2010) 1.34
Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis. J Clin Microbiol (2006) 1.33
Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS (2007) 1.33
Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One (2011) 1.32
Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis (2013) 1.31
Molecular subtyping of Treponema pallidum from North and South Carolina. J Clin Microbiol (2005) 1.30
Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. AIDS (2006) 1.30
Joint effects of alcohol consumption and high-risk sexual behavior on HIV seroconversion among men who have sex with men. AIDS (2013) 1.27
HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr (2005) 1.23
High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010. J Acquir Immune Defic Syndr (2013) 1.23
Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis (2013) 1.23
Trichomonas vaginalis genital infections: progress and challenges. Clin Infect Dis (2011) 1.22
Expression of p16(INK4a) as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. Aging Cell (2012) 1.21
Perceived oral health status, unmet needs, and barriers to dental care among HIV/AIDS patients in a North Carolina cohort: impacts of race. J Public Health Dent (2003) 1.20
Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med (2008) 1.19
Phylogenetic insights into regional HIV transmission. AIDS (2012) 1.18